ArticleVaccine2023

Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.

Kenji Kuriyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.